Weight management

Tirzepatide: the research history.

Tirzepatide’s weight-management literature includes dose-specific trial results. The dose groups and observation period need to stay attached to each reported percentage.

2,341records matching the ingredient search

1connected formulations

6displayed publication records

How the research connects to the formula

SURMOUNT-1 tested once-weekly subcutaneous 5 mg, 10 mg and 15 mg regimens over seventy-two weeks in adults without diabetes. Each dose group had its own result, compared with a placebo group in the same trial.

STEP 1 and SURMOUNT-1 used separate populations and follow-up periods. Placing their results beside one another creates a cross-trial comparison, which is different from randomizing participants between the two ingredients in one study.

Current HealthRX.com formulation map
Product	Listed formulation	Connected ingredient research
Tirzepatide	5mg/vial	Tirzepatide

Publication history

When the ingredient appeared in the literature

The chart counts records mentioning the search terms in their title or abstract. It includes research beyond weight management. Use the period controls to inspect the count.

2026: 912 indexed publications. 2026 includes publications dated through October 5. The earlier bars cover longer periods than the annual bars.

View the chart as a data table

Period	Publications
1900-1959	0
1960-1969	0
1970-1979	0
1980-1989	0
1990-1999	0
2000-2009	0
2010-2014	0
2015-2019	0
2020	9
2021	30
2022	102
2023	180
2024	335
2025	773
2026	912

Search query and data source

Source: Europe PMC’s PubMed-indexed records. Retrieved October 5, 2026. The index’s firstPublicationDate field supplies the dates and chart periods; it can normalize a month-only record to the first day of the month. Dates through October 5 are included. Counts can change as the index adds or corrects records.

TITLE_ABS:(tirzepatide) AND SRC:MED AND FIRST_PDATE:[1900-01-01 TO 2026-10-05]

Open this literature search · Download the data

Dated publications

Read individual records in context

The timeline combines selected references with a sample from the ingredient search. Dates use the index’s firstPublicationDate field; the PubMed record may distinguish an earlier online date from the print date. Written study notes appear alongside the records that have them. Other entries show the indexed bibliography and link to the paper.

Clinical Trial, Phase III · Randomized Controlled Trial · Journal Article

Tirzepatide Once Weekly for the Treatment of Obesity.

Jastreboff AM, Aronne LJ, Ahmad NN, Wharton S, Connery L, Alves B, Kiyosue A, Zhang S, Liu B, Bunck MC, Stefanski A, SURMOUNT-1 Investigators. The New England journal of medicine. PMID 35658024.

Study design: Randomized controlled trial, 2,539 adults
What was tested: Once-weekly subcutaneous tirzepatide 5, 10 or 15 mg versus placebo over 72 weeks.
What was reported: Mean weight changes were -15.0%, -19.5% and -20.9% at the respective doses, compared with -3.1% for placebo.
How it connects to the catalog: The dose-specific results are from one trial. Comparing them directly with a separate semaglutide trial does not create a head-to-head comparison.

Read the PubMed record · Publisher record

Study comparison

Publication	Design and regimen	Reported finding	Interpretation
2022-06-04: Tirzepatide Once Weekly for the Treatment of Obesity.	Randomized controlled trial, 2,539 adults. Once-weekly subcutaneous tirzepatide 5, 10 or 15 mg versus placebo over 72 weeks.	Mean weight changes were -15.0%, -19.5% and -20.9% at the respective doses, compared with -3.1% for placebo.	The dose-specific results are from one trial. Comparing them directly with a separate semaglutide trial does not create a head-to-head comparison.

Questions that shape the comparison

Is the comparison within one randomized trial or across separate trials? Which dose and follow-up period belong to each outcome?

Source records

Tirzepatide Once Weekly for the Treatment of Obesity.Jastreboff AM, Aronne LJ, Ahmad NN, Wharton S, Connery L, Alves B, Kiyosue A, Zhang S, Liu B, Bunck MC, Stefanski A, SURMOUNT-1 Investigators.The New England journal of medicine. 2022-06-04. PMID 35658024. Clinical Trial, Phase III, Randomized Controlled Trial, Journal Article.

Increased energy expenditure through intermittent cold exposure does not enhance tirzepatide-induced weight loss in obese mice.Bellucci A, Alfares H, Gale C, Akcan M, Waters B, Eisner K, Baranowski BJ, Jeromson S, Babicki-Moore A, Wright DC.American journal of physiology. Regulatory, integrative and comparative physiology. 2026-09-10. PMID 42722006. Journal Article.

TirzepatideFarzam K, Patel P.. 2026-09-14. PMID 36251836. Study Guide.

The dual incretin agonist tirzepatide blunts nicotine-induced behaviours and neurochemistry in male mice.Edvardsson CE, Emous TA, Witley S, Ericson M, Adermark L, Jerlhag E.British journal of pharmacology. 2026-09-28. PMID 42805610. Journal Article.

Real-world effectiveness and safety of low-dose tirzepatide in Japanese people with type 2 diabetes: a multicenter, retrospective, single-arm, observational study-East Shizuoka Tirzepatide (ESTATE) study.Iwamoto T, Yamasaki N, Nojiri S, Urasaki W, Aso K, Komatsu K, Enosawa N, Kanzaki M, Takarabe D, Nagakura J, Sato K, Ito N, Watada H, Nomiyama T, Collaborators of East Shizuoka Tirzepatide study.Endocrine journal. 2026-09-29. PMID 42816319. Journal Article.

Comparative Efficacy of Tirzepatide Versus Semaglutide for Weight Loss in Adults With Overweight or Obesity: A Systematic Review and Meta-Analysis of Head-to-Head Studies.Paccola GP, de Oliveira RF, Mochetti MM, Razera FPM, Vecchi R, Montanher RCP.Clinical obesity. 2026-10-01. PMID 42670242. Meta-Analysis, Comparative Study, research-article, Systematic Review, Journal Article.

Research data assembled by HealthRX.com from the displayed source records, October 5, 2026. The atlas contains a dated literature search and selected studies; it is not an exhaustive systematic review.